Eli Lilly's Oral GLP-1 Drug Orforglipron Could Launch in China by Late 2026 at the Earliest
Miles Bennett
Eli Lilly confirmed its oral weight-loss pill orforglipron could launch in China as early as late 2026, having already filed ahead of rival Novo Nordisk — making Chinese patients among the first globally to access an oral GLP-1.
What exactly did the timeline reveal?
Eli Lilly EVP Patrik Jonsson told Reuters the launch window is late 2026 to early 2027.
Lilly submitted its marketing application to China's NMPA in late 2025 — ahead of Novo Nordisk's filing.
This means → if approval lands on schedule, China will be among the earliest markets worldwide to get this oral drug, not a late follower waiting after the West.
How far behind is Novo Nordisk?
Novo CEO Mike Doustdar said in Beijing last week that the company plans to apply for oral Wegovy approval in China "soon" — but has not yet formally filed.
Orforglipron won US FDA approval in April this year; Novo's oral Wegovy was approved earlier in the US and UK and is already on sale stateside.
In plain terms = Novo leads on oral GLP-1 in the US, but in the Chinese regulatory race, Lilly has flipped the order.
Oral vs injection — why are both giants betting on pills?
An oral form (swallowing a tablet instead of injecting) has a built-in advantage in patient acceptance — the core logic behind both Lilly's and Novo's push into oral GLP-1.
This means → whoever puts an oral version on shelves first captures the pool of patients who resist needles — a decisive edge in a mass consumer market like China.
How big is the Chinese GLP-1 market right now?
Jefferies data show GLP-1 drug sales via Alibaba and JD.com totaled roughly RMB 1.4 billion (~$207 million) in Q1 2026.
Lilly, Pfizer, and Innovent Biologics have all declined to disclose specific sales figures; the market remains in its early stage.
This reflects a market with buzz but not yet scale — oral-drug approval could be the inflection point that truly opens mass adoption.
How does Lilly plan to sell it?
Jonsson stated explicitly that orforglipron faces no supply bottleneck in China.
Distribution will run through Lilly's existing partnerships with Alibaba (9988.HK) and JD Health (6618.HK).
In plain terms = Lilly doesn't need to build channels from scratch — the e-commerce pipes are already laid, and the drug can hit shelves the moment it's approved. The only remaining variable: whether NMPA approval actually lands by late 2026.
Content is for reference only, not financial advice.